Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …

There has been a rapid progress in developing genetically engineered T cells in recent
years both in basic and clinical cancer studies. Chimeric antigen receptor (CAR)-T cells …

The immune checkpoint inhibitor (ICI) pembrolizumab is US FDA approved for treatment of
solid tumors with high tumor mutational burden (TMB-high;≥ 10 variants/Mb). However, the …

Background Tumor mutational burden (TMB) measurements aid in identifying patients who
are likely to benefit from immunotherapy; however, there is empirical variability across panel …

PURPOSE Emerging evidence suggests a correlation between the tumor mutational burden
(TMB) and the response to programmed cell death-1 protein (PD-1) monotherapy across …

Next-generation sequencing (NGS) technologies are high-throughput methods for DNA
sequencing and have become a widely adopted tool in cancer research. The sheer amount …

PURPOSE Molecular tumor profiling is becoming a routine part of clinical cancer care,
typically involving tumor-only panel testing without matched germline. We hypothesized that …

With the recent FDA approval of tumor mutational burden-high (TMB-H) status as a
biomarker for treatment with a PD-1 inhibitor regardless of tumor type, accurate assessment …

We describe the analytic validation of NeXT Dx, a comprehensive genomic profiling assay to
aid therapy and clinical trial selection for patients diagnosed with solid tumor cancers …

PURPOSE Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive
biomarker for baseline characterization and longitudinal monitoring of a tumor throughout …